Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Patient Centered Randomized Controlled Trial
Patient Assistance to Reduce Breast Cancer Disparities
Status: Archived
Elmhurst Memorial Hospital
mi
from
Elmhurst, IL
Patient Centered Randomized Controlled Trial
Patient Assistance to Reduce Breast Cancer Disparities
Status: Archived
Updated: 1/1/1970
Elmhurst Memorial Hospital
mi
from
Elmhurst, IL
Patient Centered Randomized Controlled Trial
Patient Assistance to Reduce Breast Cancer Disparities
Status: Archived
Queens Hospital Center
mi
from
Queens, NY
Patient Centered Randomized Controlled Trial
Patient Assistance to Reduce Breast Cancer Disparities
Status: Archived
Updated: 1/1/1970
Queens Hospital Center
mi
from
Queens, NY
Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis
Application of the Microculture Kinetic (MiCK) Assay for Apoptosis to Drug Testing Sensitivity of Solid Tumors
Status: Archived
Nashville Breast Center
mi
from
Nashville, TN
Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis
Application of the Microculture Kinetic (MiCK) Assay for Apoptosis to Drug Testing Sensitivity of Solid Tumors
Status: Archived
Updated: 1/1/1970
Nashville Breast Center
mi
from
Nashville, TN
Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis
Application of the Microculture Kinetic (MiCK) Assay for Apoptosis to Drug Testing Sensitivity of Solid Tumors
Status: Archived
Nashville Oncology Associates
mi
from
Nashville, TN
Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis
Application of the Microculture Kinetic (MiCK) Assay for Apoptosis to Drug Testing Sensitivity of Solid Tumors
Status: Archived
Updated: 1/1/1970
Nashville Oncology Associates
mi
from
Nashville, TN
Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis
Application of the Microculture Kinetic (MiCK) Assay for Apoptosis to Drug Testing Sensitivity of Solid Tumors
Status: Archived
Cancer Care Centers of South Texas
mi
from
San Antonio, TX
Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis
Application of the Microculture Kinetic (MiCK) Assay for Apoptosis to Drug Testing Sensitivity of Solid Tumors
Status: Archived
Updated: 1/1/1970
Cancer Care Centers of South Texas
mi
from
San Antonio, TX
Genetic Counseling or Usual Care in Helping Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I, Stage II, or Stage IIIA Breast Cancer Make Treatment Decisions
Genetic Counseling for Newly Diagnosed Breast Cancer Patients
Status: Archived
Georgetown Univ Med Ctr
mi
from
Washington,
Genetic Counseling or Usual Care in Helping Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I, Stage II, or Stage IIIA Breast Cancer Make Treatment Decisions
Genetic Counseling for Newly Diagnosed Breast Cancer Patients
Status: Archived
Updated: 1/1/1970
Georgetown Univ Med Ctr
mi
from
Washington,
Genetic Counseling or Usual Care in Helping Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I, Stage II, or Stage IIIA Breast Cancer Make Treatment Decisions
Genetic Counseling for Newly Diagnosed Breast Cancer Patients
Status: Archived
Clinical Trial Facility
mi
from
Chevy Chase, MD
Genetic Counseling or Usual Care in Helping Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I, Stage II, or Stage IIIA Breast Cancer Make Treatment Decisions
Genetic Counseling for Newly Diagnosed Breast Cancer Patients
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Chevy Chase, MD
Genetic Counseling or Usual Care in Helping Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I, Stage II, or Stage IIIA Breast Cancer Make Treatment Decisions
Genetic Counseling for Newly Diagnosed Breast Cancer Patients
Status: Archived
Hackensack Univeristy Medical Center
mi
from
Hackensack, NJ
Genetic Counseling or Usual Care in Helping Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I, Stage II, or Stage IIIA Breast Cancer Make Treatment Decisions
Genetic Counseling for Newly Diagnosed Breast Cancer Patients
Status: Archived
Updated: 1/1/1970
Hackensack Univeristy Medical Center
mi
from
Hackensack, NJ
Genetic Counseling or Usual Care in Helping Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I, Stage II, or Stage IIIA Breast Cancer Make Treatment Decisions
Genetic Counseling for Newly Diagnosed Breast Cancer Patients
Status: Archived
Mount Sinai Hospital
mi
from
New York, NY
Genetic Counseling or Usual Care in Helping Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I, Stage II, or Stage IIIA Breast Cancer Make Treatment Decisions
Genetic Counseling for Newly Diagnosed Breast Cancer Patients
Status: Archived
Updated: 1/1/1970
Mount Sinai Hospital
mi
from
New York, NY
Improving Communication With Patients With Breast Cancer
Facilitating Caring Communication for People With Cancer: The Case of Breast Cancer
Status: Archived
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
mi
from
Chicago, IL
Improving Communication With Patients With Breast Cancer
Facilitating Caring Communication for People With Cancer: The Case of Breast Cancer
Status: Archived
Updated: 1/1/1970
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
mi
from
Chicago, IL
Phase II Trial - Breast Cancer Chemoprevention by Lovastatin
A Phase II Trial of Lovastatin for Modification of Abnormal Breast Duct Cytology and Risk-Associated Biomarkers in Women at High Inherited Risk of Breast Cancer
Status: Archived
Stanford university Hospital and Clinics
mi
from
Stanford, CA
Phase II Trial - Breast Cancer Chemoprevention by Lovastatin
A Phase II Trial of Lovastatin for Modification of Abnormal Breast Duct Cytology and Risk-Associated Biomarkers in Women at High Inherited Risk of Breast Cancer
Status: Archived
Updated: 1/1/1970
Stanford university Hospital and Clinics
mi
from
Stanford, CA
Liposomal Doxorubicin Before Mastectomy in Treating Women With Invasive Breast Cancer
A Phase I Study Assessing the Feasibility and Safety of Intraductal Administration of Pegylated Liposomal Doxorubicin (Doxil) in Women With Breast Cancer
Status: Archived
Indiana University Adult Psychiatry Clinic
mi
from
Indianapolis, IN
Liposomal Doxorubicin Before Mastectomy in Treating Women With Invasive Breast Cancer
A Phase I Study Assessing the Feasibility and Safety of Intraductal Administration of Pegylated Liposomal Doxorubicin (Doxil) in Women With Breast Cancer
Status: Archived
Updated: 1/1/1970
Indiana University Adult Psychiatry Clinic
mi
from
Indianapolis, IN
Liposomal Doxorubicin Before Mastectomy in Treating Women With Invasive Breast Cancer
A Phase I Study Assessing the Feasibility and Safety of Intraductal Administration of Pegylated Liposomal Doxorubicin (Doxil) in Women With Breast Cancer
Status: Archived
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Liposomal Doxorubicin Before Mastectomy in Treating Women With Invasive Breast Cancer
A Phase I Study Assessing the Feasibility and Safety of Intraductal Administration of Pegylated Liposomal Doxorubicin (Doxil) in Women With Breast Cancer
Status: Archived
Updated: 1/1/1970
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Luteal v. Follicular Phase Surgical Oophorectomy & Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor + Br. CA
Phase III Randomized Study of Luteal Phase vs. Follicular Phase Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor-Positive Breast Cancer
Status: Archived
Ohio State University
mi
from
Columbus, OH
Luteal v. Follicular Phase Surgical Oophorectomy & Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor + Br. CA
Phase III Randomized Study of Luteal Phase vs. Follicular Phase Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor-Positive Breast Cancer
Status: Archived
Updated: 1/1/1970
Ohio State University
mi
from
Columbus, OH
Luteal v. Follicular Phase Surgical Oophorectomy & Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor + Br. CA
Phase III Randomized Study of Luteal Phase vs. Follicular Phase Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor-Positive Breast Cancer
Status: Archived
St. Joseph's Hospital
mi
from
Ann Arbor, MI
Luteal v. Follicular Phase Surgical Oophorectomy & Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor + Br. CA
Phase III Randomized Study of Luteal Phase vs. Follicular Phase Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor-Positive Breast Cancer
Status: Archived
Updated: 1/1/1970
St. Joseph's Hospital
mi
from
Ann Arbor, MI
Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer
Efficacy of Palonosetron in the Prevention of Acute and Delayed Chemotherapy-Induced Nausea and Vomiting Following Dose Dense Adriamycin-Cyclophosphamide Chemotherapy in Early Stage Breast Cancer Patients
Status: Archived
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer
Efficacy of Palonosetron in the Prevention of Acute and Delayed Chemotherapy-Induced Nausea and Vomiting Following Dose Dense Adriamycin-Cyclophosphamide Chemotherapy in Early Stage Breast Cancer Patients
Status: Archived
Updated: 1/1/1970
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
One Dose of Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine
A Phase I Study of Infusion of HER-2/Neu Specific T-cells in Patients With Advanced Stage HER-2/Neu Expressing Cancers Who Have Received a HER-2/Neu Vaccine
Status: Archived
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
One Dose of Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine
A Phase I Study of Infusion of HER-2/Neu Specific T-cells in Patients With Advanced Stage HER-2/Neu Expressing Cancers Who Have Received a HER-2/Neu Vaccine
Status: Archived
Updated: 1/1/1970
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Patient Navigator Research Program
Patient Navigator Research Program
Status: Archived
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Patient Navigator Research Program
Patient Navigator Research Program
Status: Archived
Updated: 1/1/1970
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Advanced Solid Tumors
A Phase I Trial of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine in Advanced Malignancies
Status: Archived
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Advanced Solid Tumors
A Phase I Trial of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine in Advanced Malignancies
Status: Archived
Updated: 1/1/1970
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Advanced Solid Tumors
A Phase I Trial of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine in Advanced Malignancies
Status: Archived
USC Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Advanced Solid Tumors
A Phase I Trial of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine in Advanced Malignancies
Status: Archived
Updated: 1/1/1970
USC Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Advanced Solid Tumors
A Phase I Trial of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine in Advanced Malignancies
Status: Archived
University of California Davis Cancer Center
mi
from
Sacramento, CA
5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Advanced Solid Tumors
A Phase I Trial of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine in Advanced Malignancies
Status: Archived
Updated: 1/1/1970
University of California Davis Cancer Center
mi
from
Sacramento, CA
5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Advanced Solid Tumors
A Phase I Trial of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine in Advanced Malignancies
Status: Archived
National Cancer Institute (NCI)
mi
from
Bethesda, MD
5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Advanced Solid Tumors
A Phase I Trial of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine in Advanced Malignancies
Status: Archived
Updated: 1/1/1970
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Kukui Ahi Navigator Cancer Screening and Treatment Demonstration Project
Status: Archived
Molokai General Hospital
mi
from
Kaunakakai, HI
Kukui Ahi Navigator Cancer Screening and Treatment Demonstration Project
Status: Archived
Updated: 1/1/1970
Molokai General Hospital
mi
from
Kaunakakai, HI
Breast Cancer Lymphedema: Role of Insulin Resistance/FOXC2
Breast Cancer Lymphedema: Role of Insulin Resistance/FOXC2
Status: Archived
Stanford university Hospital and Clinics
mi
from
Stanford, CA
Breast Cancer Lymphedema: Role of Insulin Resistance/FOXC2
Breast Cancer Lymphedema: Role of Insulin Resistance/FOXC2
Status: Archived
Updated: 1/1/1970
Stanford university Hospital and Clinics
mi
from
Stanford, CA
Exercise Intervention in Women With Metastatic Breast Cancer
Pilot Study of a Moderate-Intensity Exercise Intervention in Women With Metastatic Breast Cancer
Status: Archived
Dana-Farber Cancer Institute
mi
from
Boston, MA
Exercise Intervention in Women With Metastatic Breast Cancer
Pilot Study of a Moderate-Intensity Exercise Intervention in Women With Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Dana-Farber Cancer Institute
mi
from
Boston, MA
Exercise Intervention in Women With Metastatic Breast Cancer
Pilot Study of a Moderate-Intensity Exercise Intervention in Women With Metastatic Breast Cancer
Status: Archived
Beth Israel Deaconess Medical Center`
mi
from
Boston, MA
Exercise Intervention in Women With Metastatic Breast Cancer
Pilot Study of a Moderate-Intensity Exercise Intervention in Women With Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Beth Israel Deaconess Medical Center`
mi
from
Boston, MA
Acupuncture in the Management of Post Operative Symptoms in Breast Cancer Patients
A Randomized, Intent to Treat, Controlled Study of the Efficacy of Verum Acupuncture Compared to Sham Acupuncture in the Management of Post Operative Symptoms in Breast Cancer Subjects That Have Undergone Axillary Surgery
Status: Archived
Legacy Emanuel Hospital and Health Center and Children's Hospital
mi
from
Portland, OR
Acupuncture in the Management of Post Operative Symptoms in Breast Cancer Patients
A Randomized, Intent to Treat, Controlled Study of the Efficacy of Verum Acupuncture Compared to Sham Acupuncture in the Management of Post Operative Symptoms in Breast Cancer Subjects That Have Undergone Axillary Surgery
Status: Archived
Updated: 1/1/1970
Legacy Emanuel Hospital and Health Center and Children's Hospital
mi
from
Portland, OR
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
Oncotherapeutics
mi
from
West Hollywood, CA
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
Updated: 1/1/1970
Oncotherapeutics
mi
from
West Hollywood, CA
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
Rocky Mountain Cancer Center
mi
from
Denver, CO
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
Updated: 1/1/1970
Rocky Mountain Cancer Center
mi
from
Denver, CO
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
Norwalk Hospital
mi
from
Norwalk, CT
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
Updated: 1/1/1970
Norwalk Hospital
mi
from
Norwalk, CT
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
Montefiore Medical Center
mi
from
Bronx, NY
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
Updated: 1/1/1970
Montefiore Medical Center
mi
from
Bronx, NY
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
University of Pittsburgh, Emergency Responder Human Performance Lab
mi
from
Pittsburgh, PA
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
Updated: 1/1/1970
University of Pittsburgh, Emergency Responder Human Performance Lab
mi
from
Pittsburgh, PA
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
Rhode Island Hospital
mi
from
Providence, RI
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
Updated: 1/1/1970
Rhode Island Hospital
mi
from
Providence, RI
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
Huntsman Cancer Hospital
mi
from
Salt Lake City, UT
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
Updated: 1/1/1970
Huntsman Cancer Hospital
mi
from
Salt Lake City, UT
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
Fletcher Allen Health Care
mi
from
Burlington, VT
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
Updated: 1/1/1970
Fletcher Allen Health Care
mi
from
Burlington, VT
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
Virginia Cancer Center
mi
from
Richmond, VA
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
Updated: 1/1/1970
Virginia Cancer Center
mi
from
Richmond, VA
Identification of Key Blood Molecular Markers for Immunotherapy
Identification of Key Blood Molecular Markers for Immunotherapy
Status: Archived
Stanford University School of Medicine
mi
from
Stanford, CA
Identification of Key Blood Molecular Markers for Immunotherapy
Identification of Key Blood Molecular Markers for Immunotherapy
Status: Archived
Updated: 1/1/1970
Stanford University School of Medicine
mi
from
Stanford, CA
IDO Inhibitor Study for Relapsed or Refractory Solid Tumors
A Phase I Study of 1-methyl-D-tryptophan (D-1MT) in Patients With Relapsed or Refractory Solid Tumors
Status: Archived
Vanderbilt University Medical Center
mi
from
Ventura, CA
IDO Inhibitor Study for Relapsed or Refractory Solid Tumors
A Phase I Study of 1-methyl-D-tryptophan (D-1MT) in Patients With Relapsed or Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
Vanderbilt University Medical Center
mi
from
Ventura, CA
Phase II Neoadjuvant in Inflammatory Breast Cancer
A Phase II Study of Neoadjuvant Lapatinib Plus Chemotherapy (Sequential FEC75 and Paclitaxel) in Women With Inflammatory Breast Cancer Whose Tumors Overexpress ErbB2 (Her2/Neu)
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Phase II Neoadjuvant in Inflammatory Breast Cancer
A Phase II Study of Neoadjuvant Lapatinib Plus Chemotherapy (Sequential FEC75 and Paclitaxel) in Women With Inflammatory Breast Cancer Whose Tumors Overexpress ErbB2 (Her2/Neu)
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Study Of MK-0752 In Combination With Tamoxifen Or Letrozole to Treat Early Stage Breast Cancer
A Pilot Study of MK-0752 in Combination With Tamoxifen or Letrozole in Patients With Early Stage Breast Cancer Prior to Surgery
Status: Archived
Cardinal Bernardin Cancer Center at Loyola University Medical Center
mi
from
Maywood, IL
Study Of MK-0752 In Combination With Tamoxifen Or Letrozole to Treat Early Stage Breast Cancer
A Pilot Study of MK-0752 in Combination With Tamoxifen or Letrozole in Patients With Early Stage Breast Cancer Prior to Surgery
Status: Archived
Updated: 1/1/1970
Cardinal Bernardin Cancer Center at Loyola University Medical Center
mi
from
Maywood, IL
Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen
Validating CYP2D6 Genotype-Guided Tamoxifen Therapy for a Multiracial U.S. Population
Status: Archived
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen
Validating CYP2D6 Genotype-Guided Tamoxifen Therapy for a Multiracial U.S. Population
Status: Archived
Updated: 1/1/1970
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen
Validating CYP2D6 Genotype-Guided Tamoxifen Therapy for a Multiracial U.S. Population
Status: Archived
Carolinas Medical Center
mi
from
Charlotte, NC
Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen
Validating CYP2D6 Genotype-Guided Tamoxifen Therapy for a Multiracial U.S. Population
Status: Archived
Updated: 1/1/1970
Carolinas Medical Center
mi
from
Charlotte, NC
Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen
Validating CYP2D6 Genotype-Guided Tamoxifen Therapy for a Multiracial U.S. Population
Status: Archived
Duke Univ Med Ctr
mi
from
Durham, NC
Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen
Validating CYP2D6 Genotype-Guided Tamoxifen Therapy for a Multiracial U.S. Population
Status: Archived
Updated: 1/1/1970
Duke Univ Med Ctr
mi
from
Durham, NC
Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen
Validating CYP2D6 Genotype-Guided Tamoxifen Therapy for a Multiracial U.S. Population
Status: Archived
Moses Cone Medical System
mi
from
Greensboro, NC
Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen
Validating CYP2D6 Genotype-Guided Tamoxifen Therapy for a Multiracial U.S. Population
Status: Archived
Updated: 1/1/1970
Moses Cone Medical System
mi
from
Greensboro, NC
Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen
Validating CYP2D6 Genotype-Guided Tamoxifen Therapy for a Multiracial U.S. Population
Status: Archived
Leo W. Jenkins Cancer Center at ECU Medical School
mi
from
Greenville, NC
Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen
Validating CYP2D6 Genotype-Guided Tamoxifen Therapy for a Multiracial U.S. Population
Status: Archived
Updated: 1/1/1970
Leo W. Jenkins Cancer Center at ECU Medical School
mi
from
Greenville, NC
Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen
Validating CYP2D6 Genotype-Guided Tamoxifen Therapy for a Multiracial U.S. Population
Status: Archived
Rex UNC Health Care Center
mi
from
Raleigh, NC
Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen
Validating CYP2D6 Genotype-Guided Tamoxifen Therapy for a Multiracial U.S. Population
Status: Archived
Updated: 1/1/1970
Rex UNC Health Care Center
mi
from
Raleigh, NC
Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen
Validating CYP2D6 Genotype-Guided Tamoxifen Therapy for a Multiracial U.S. Population
Status: Archived
Spartanburg Regional Health Service District
mi
from
Spartanburg, SC
Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen
Validating CYP2D6 Genotype-Guided Tamoxifen Therapy for a Multiracial U.S. Population
Status: Archived
Updated: 1/1/1970
Spartanburg Regional Health Service District
mi
from
Spartanburg, SC
Do Aromatase Inhibitors (AIs) Decrease Intestinal Calcium Absorption?
Do Aromatase Inhibitors (AIs) Decrease Intestinal Calcium Absorption?
Status: Archived
University of Wisconsin-Madison
mi
from
Madison, WI
Do Aromatase Inhibitors (AIs) Decrease Intestinal Calcium Absorption?
Do Aromatase Inhibitors (AIs) Decrease Intestinal Calcium Absorption?
Status: Archived
Updated: 1/1/1970
University of Wisconsin-Madison
mi
from
Madison, WI
Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer
A Randomized, Double-Blind, Multi-Center Phase II Trial of Exemestane (Aromasin®) Plus Dasatinib Versus Exemestane Plus Placebo in Advanced ER+ Breast Cancer After Disease Progression on a Non-Steroidal Aromatase Inhibitor
Status: Archived
Compassionate Cancer Care Medical Group, Inc.
mi
from
Corona, CA
Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer
A Randomized, Double-Blind, Multi-Center Phase II Trial of Exemestane (Aromasin®) Plus Dasatinib Versus Exemestane Plus Placebo in Advanced ER+ Breast Cancer After Disease Progression on a Non-Steroidal Aromatase Inhibitor
Status: Archived
Updated: 1/1/1970
Compassionate Cancer Care Medical Group, Inc.
mi
from
Corona, CA
Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer
A Randomized, Double-Blind, Multi-Center Phase II Trial of Exemestane (Aromasin®) Plus Dasatinib Versus Exemestane Plus Placebo in Advanced ER+ Breast Cancer After Disease Progression on a Non-Steroidal Aromatase Inhibitor
Status: Archived
Fox Chase Cancer Center
mi
from
Philadephia, PA
Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer
A Randomized, Double-Blind, Multi-Center Phase II Trial of Exemestane (Aromasin®) Plus Dasatinib Versus Exemestane Plus Placebo in Advanced ER+ Breast Cancer After Disease Progression on a Non-Steroidal Aromatase Inhibitor
Status: Archived
Updated: 1/1/1970
Fox Chase Cancer Center
mi
from
Philadephia, PA